Clinical trial
A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
NCT07890376 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- November 30, 2026
- Completion date
- June 30, 2028
- Enrollment
- 460 (estimated)
- Sites
- 46
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 10 arms.
-
LY4086940 Dose 1
Participants will receive LY4086940 orally
-
LY4086940 Dose 2
Participants will receive LY4086940 orally
-
LY4086940 Dose 3, Titration Schedule A
Participants will receive LY4086940 orally
-
LY4086940 Dose 3, Titration Schedule B
Participants will receive LY4086940 orally
-
LY4086940 Dose 4
Participants will receive LY4086940 orally
+5 more arms
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Percent Change from Baseline in Body Weight
Lead sponsor's other trials
Eli Lilly and Company, most recent start first.
+2,102 more trials See the organization page
Similar trials
Same condition (Weight Loss) and phase, most recent start first.
+103 more trials See the condition page